These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 9627539

  • 41. Effects of various lipid-lowering treatments in diabetics.
    Steiner G.
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S35-9. PubMed ID: 1710744
    [Abstract] [Full Text] [Related]

  • 42. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM.
    Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
    [Abstract] [Full Text] [Related]

  • 43. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
    Aoki T, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y.
    Arzneimittelforschung; 2001 Feb; 51(3):197-203. PubMed ID: 11304935
    [Abstract] [Full Text] [Related]

  • 44. Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
    Korolenko TA, Tuzikov FV, Cherkanova MS, Johnston TP, Tuzikova NA, Loginova VM, Filjushina EE, Kaledin VI.
    Can J Physiol Pharmacol; 2012 Feb; 90(2):141-53. PubMed ID: 22320860
    [Abstract] [Full Text] [Related]

  • 45. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG.
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [Abstract] [Full Text] [Related]

  • 46. Advances in lipid-lowering therapy in atherosclerosis.
    Davignon J.
    Adv Exp Med Biol; 2001 Jul; 498():49-58. PubMed ID: 11900401
    [Abstract] [Full Text] [Related]

  • 47. Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion.
    Ge CJ, Lü SZ, Feng LX, Huo Y, Song XT, Chen X, Meng K, Yuan F.
    Chin Med J (Engl); 2012 Jul; 125(14):2472-6. PubMed ID: 22882924
    [Abstract] [Full Text] [Related]

  • 48. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
    Devroey D, Velkeniers B, Duquet W, Betz W.
    Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
    [Abstract] [Full Text] [Related]

  • 49. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
    McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML.
    Am J Cardiol; 2001 Aug 01; 88(3):270-4. PubMed ID: 11472706
    [Abstract] [Full Text] [Related]

  • 50. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.
    Frohlich J, Fodor G, McPherson R, Genest J, Langner N.
    Can J Cardiol; 1998 Apr 01; 14 Suppl A():17A-21A. PubMed ID: 9594929
    [Abstract] [Full Text] [Related]

  • 51. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H.
    Fundam Clin Pharmacol; 2009 Dec 01; 23(6):687-92. PubMed ID: 19682084
    [Abstract] [Full Text] [Related]

  • 52. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.
    O'Keefe JH, Captain BK, Jones PG, Harris WS.
    Prev Cardiol; 2004 Dec 01; 7(4):154-60. PubMed ID: 15539961
    [Abstract] [Full Text] [Related]

  • 53. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ, Redfern JS, McGovern ME, Giral P.
    Pharmacol Ther; 2010 Jun 01; 126(3):314-45. PubMed ID: 20153365
    [Abstract] [Full Text] [Related]

  • 54. [The pharmacological treatment of hypercholesterolemia].
    Pérez Jiménez F.
    Rev Esp Cardiol; 1995 Jun 01; 48 Suppl 5():31-8. PubMed ID: 7494938
    [Abstract] [Full Text] [Related]

  • 55. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
    Lea AP, McTavish D.
    Drugs; 1997 May 01; 53(5):828-47. PubMed ID: 9129869
    [Abstract] [Full Text] [Related]

  • 56. Diabetic dyslipidemia.
    Kreisberg RA.
    Am J Cardiol; 1998 Dec 17; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [Abstract] [Full Text] [Related]

  • 57. Insulin resistance syndrome and type 2 diabetes mellitus.
    Erkelens DW.
    Am J Cardiol; 2001 Oct 11; 88(7B):38J-42J. PubMed ID: 11595198
    [Abstract] [Full Text] [Related]

  • 58. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L, Respondek W, Białobrzeska-Paluszkiewicz J, Grzybowska B, Jakóbisiak-Ostasz B, Stolarska I.
    Pol Merkur Lekarski; 2003 Jul 11; 15(85):42-6. PubMed ID: 14593958
    [Abstract] [Full Text] [Related]

  • 59. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Kawashiri MA, Kobayashi J, Nohara A, Noguchi T, Tada H, Nakanishi C, Inazu A, Mabuchi H, Yamagishi M.
    Clin Chim Acta; 2011 May 12; 412(11-12):1068-75. PubMed ID: 21354122
    [Abstract] [Full Text] [Related]

  • 60. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
    Atalar E, Ozmen F, Haznedaroglu I, Açil T, Ozer N, Ovünç K, Aksöyek S, Kes S.
    Int J Cardiol; 2002 Aug 12; 84(2-3):227-31. PubMed ID: 12127376
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.